• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
    • Donate
  • Contact
  • Show SearchSearch

Remdesivir (Veklury®)

May 1, 2022

Selected References

  • Anderson J, et al. 2020. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. Case reports in women’s health, 27, e00221.
  • Budi, DS, et al. 2022. Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19. Heliyon, 8(1), e08835.
  • Burwick RM, et al. 2021. Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. Clin Infect Dis. 6;73(11):e3996-e4004
  • Clinical Solutions: Remdesivir monograph. Revised 5/7/2020. https://www.elsevier.com/__data/assets/pdf_file/0008/996767/Remdesivir-Drug-Monograph_28MAY2020.pdf
  • Dornemann J, et al. 2017. First newborn baby to receive experimental therapies survives Ebola virus disease. J Infect Dis, 215:171–4.
  • FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness. 2020. https://www.fda.gov/drugs/news-events-human-drugs/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness?msclkid=172b6876c65d11ec832b5913d0d746c5
  • Frauenfelder C, et al. 2020. Infant with SARS-CoV-2 infection causing severe lung disease treated with remdesivir. Pediatrics. 146:e20201701.
  • Gilead Sciences, Inc. 2022. Remdesivir product labeling. https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf
  • Gutierrez R, et al. 2022. Remdesivir use in pregnancy during the SARS-CoV-2 pandemic, The Journal of Maternal-Fetal & Neonatal Medicine, DOI: 10.1080/14767058.2022.2041595.
  • Jorgensen SCJ, 2021. A review of remdesivir for COVID-19 in pregnancy and lactation. J Antimicrob Chemother. 77(1):24-30.
  • Lampejo T. 2021. Remdesivir for the treatment of COVID‐19 in pregnancy. Journal of medical virology, 93(7), 4114.
  • Mulangu S, et al. 2019. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med., 381:2293–303.
  • Naqvi M, et al. 2020.Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19), Obstetrics & Gynecology. 136(5):1025-1029.
  • Nasrallah, S, et al. 2021. Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. The Journal of Maternal-Fetal & Neonatal Medicine, 1-8.
  • Pierce-Williams RAM, et al. 2020. Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study. Am J Obstet Gynecol MFM; 2(3):100134.
  • Wada YS, et al. 2022. Remdesivir and human milk: A case study. J Hum Lact.

Footer

           

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Asthma
  • Coronavirus (COVID-19)
  • Crohn’s Disease
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Pertussis/Tdap vaccine (“Whooping Cough” vaccine)
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists
OTIS Logo

Copyright © 2023 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^